Latest news with #OrbitrapAstralMassSpectrometer
&w=3840&q=100)
Business Standard
24-05-2025
- Business
- Business Standard
HCG Q4 PAT drops 65% to ₹7.4 cr; acquires Orbitrap Astral from Thermo
Bengaluru-based HealthCare Global Enterprises (HCG) reported a 65 per cent decrease in consolidated profit after tax (PAT) to Rs 7.4 crore during the fourth quarter of the financial year ended March. HCG further announced the acquisition of the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific. 'Looking ahead, we are making focused investments in next-generation capabilities, especially in early cancer detection and precision medicine. In line with our commitment to cutting-edge diagnostics and research, we are pleased to share that we are acquiring the Orbitrap Astral Mass Spectrometer from Thermo Fisher Scientific — one of the most advanced platforms globally for high-resolution mass spectrometry,' said BS Ajaikumar, executive chairman, HealthCare Global Enterprises. 'The acquisition will significantly enhance our molecular and proteomic profiling capabilities, enabling more precise disease characterisation and paving the way for next-generation biomarker discovery and targeted therapies,' said Ajaikumar. HCG reported operating income at Rs 585.1 crore in Q4FY25, up from Rs 494.6 crore in the same period last year. The company reported that revenues for HCG Onco Specialty Centres (excluding MGM) grew by a robust 16.7 per cent year-on-year in FY25. The quarter's earnings before interest, taxes, depreciation, and amortization (EBITDA) stood at Rs 107 crore, a growth of 14 per cent while maintaining a margin a margin of 18.3 per cent. For the company's established centers, EBITDA grew 15 per cent at Rs 115.4 crore, and emerging centers witnessed a Rs 7 crore increase from Rs 4.9 crore, year-on-year. 'Continuing our strategic focus on inorganic growth, we acquired MG Hospital in Vizag in FY25, further consolidating our presence and establishing HCG as the leading cancer care provider in that region. This acquisition marks our third in just 18 months, highlighting our consistent and focused approach to expansion,' said Raj Gore, CEO HealthCare Global Enterprises. HCG further emphasised its long-term commitment to building a robust academic and research foundation. Through fellowship programs and clinical research initiatives, the organisation aims to nurture the next generation of oncology leaders.
United News of India
24-05-2025
- Business
- United News of India
HCG posts Rs 5,851 million revenue in Q4 FY25
Bengaluru, May 24 (UNI) HealthCare Global Enterprises Ltd. (HCG), India's leading speciality healthcare provider focused on oncology and fertility, announced its unaudited financial results for the quarter and full year ended March 31, 2025. The company reported consolidated revenue of Rs 5,851 million for Q4 FY25, marking an 18% year-on-year growth from Rs 4,946 million in the corresponding quarter last year. For the full financial year 2025, HCG's revenue stood at Rs 22,228 million, reflecting a robust 16% growth over the previous year. EBITDA for Q4 FY25 was recorded at Rs 1,070 million, registering a 14% increase year-on-year, with margins at 18.3%. Profit After Tax (PAT) for the quarter was INR 74 million, down from Rs 213 million in Q4 FY24. Key operational highlights include a 3.5% rise in Average Revenue Per Operating Bed (ARPOB) to Rs 44,236, and an improvement in Average Occupancy Rate (AOR) to 67% from 63.2% in the previous year's quarter. The company also expanded its infrastructure by adding two Linear Accelerators (LINACs) at Vizag and Nagpur, and one PET CT facility in Africa. Dr BS Ajaikumar, Executive Chairman of HCG, said, "We have concluded another year of strong performance and meaningful progress. HCG continues to lead India's battle against cancer with a pan-India presence. We are investing in next-generation capabilities, including advanced molecular diagnostics and precision medicine. Our acquisition of the Orbitrap Astral Mass Spectrometer will significantly enhance our disease profiling and targeted therapy development." Raj Gore, CEO, added, "FY25 was a strong year operationally and financially. Excluding Milann centres, revenues grew by 17.4% to INR 21,651 million and Adjusted EBITDA increased 18.3% to Rs 3,913 million with margins of 18.1%. Our strategic acquisitions, including MG Hospital in Vizag, strengthen our regional presence and growth outlook. We remain confident about sustaining momentum into FY26.' HCG operates 22 comprehensive cancer centres across India and Africa and 7 fertility centres under the 'Milann' brand. UNI BDN RN
